BAFF Receptor mAb Treatment Ameliorates Development and Progression of Atherosclerosis in Hyperlipidemic ApoE−/− Mice

Aims Option to attenuate atherosclerosis by depleting B2 cells is currently limited to anti-CD20 antibodies which deplete all B-cell subtypes. In the present study we evaluated the capacity of a monoclonal antibody to B cell activating factor-receptor (BAFFR) to selectively deplete atherogenic B2 cells to prevent both development and progression of atherosclerosis in the ApoE−/− mouse. Methods and Results To determine whether the BAFFR antibody prevents atherosclerosis development, we treated ApoE−/− mice with the antibody while feeding them a high fat diet (HFD) for 8 weeks. Mature CD93− CD19+ B2 cells were reduced by treatment, spleen B-cell zones disrupted and spleen CD20 mRNA expression decreased while B1a cells and non-B cells were spared. Atherosclerosis was ameliorated in the hyperlipidemic mice and CD19+ B cells, CD4+ and CD8+ T cells were reduced in atherosclerotic lesions. Expressions of proinflammatory cytokines, IL1β, TNFα, and IFNγ in the lesions were also reduced, while MCP1, MIF and VCAM-1 expressions were unaffected. Plasma immunoglobulins were reduced, but MDA-oxLDL specific antibodies were unaffected. To determine whether anti-BAFFR antibody ameliorates progression of atherosclerosis, we first fed ApoE−/− mice a HFD for 6 weeks, and then instigated anti-BAFFR antibody treatment for a further 6 week-HFD. CD93− CD19+ B2 cells were selectively decreased and atherosclerotic lesions were reduced by this treatment. Conclusion Anti-BAFFR monoclonal antibody selectively depletes mature B2 cells while sparing B1a cells, disrupts spleen B-cell zones and ameliorates atherosclerosis development and progression in hyperlipidemic ApoE−/− mice. Our findings have potential for clinical translation to manage atherosclerosis-based cardiovascular diseases.

[1]  A. Vissink,et al.  Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial , 2012, Annals of the rheumatic diseases.

[2]  Stanley B. Cohen,et al.  Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study , 2012, The Journal of Rheumatology.

[3]  Grzegorz Chodaczek,et al.  Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. , 2012, The Journal of clinical investigation.

[4]  D. Tsiantoulas,et al.  BAFF Receptor Deficiency Reduces the Development of Atherosclerosis in Mice—Brief Report , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[5]  E. Neufeld,et al.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. , 2012, Blood.

[6]  J. Lünemann,et al.  Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. , 2012, The Journal of clinical investigation.

[7]  P. Tipping,et al.  Protective role of natural IgM-producing B1a cells in atherosclerosis. , 2012, Trends in cardiovascular medicine.

[8]  F. Mackay,et al.  BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus , 2012, Immunology and cell biology.

[9]  P. Tipping,et al.  Depletion of B2 but Not B1a B Cells in BAFF Receptor-Deficient ApoE−/− Mice Attenuates Atherosclerosis by Potently Ameliorating Arterial Inflammation , 2012, PloS one.

[10]  A. Rolink,et al.  BAFF‐R expression correlates with positive selection of immature B cells , 2012, European journal of immunology.

[11]  S. Kim,et al.  B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy , 2012, Leukemia & lymphoma.

[12]  V. Lougaris,et al.  Soluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptors , 2012, The Journal of Immunology.

[13]  P. Tipping,et al.  Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis , 2011, Current opinion in lipidology.

[14]  P. Tipping,et al.  B1a B Lymphocytes Are Atheroprotective by Secreting Natural IgM That Increases IgM Deposits and Reduces Necrotic Cores in Atherosclerotic Lesions , 2011, Circulation research.

[15]  K. Huth,et al.  CD4(+) T-cells are important in regulating macrophage polarization in C57BL/6 wild-type mice. , 2011, Cellular immunology.

[16]  P. Tipping,et al.  Conventional B2 B Cell Depletion Ameliorates whereas Its Adoptive Transfer Aggravates Atherosclerosis , 2010, The Journal of Immunology.

[17]  J. Neefjes,et al.  Antigen-Specific B Cells Reactivate an Effective Cytotoxic T Cell Response against Phagocytosed Salmonella through Cross-Presentation , 2010, PloS one.

[18]  F. Mackay,et al.  B‐cell stage and context‐dependent requirements for survival signals from BAFF and the B‐cell receptor , 2010, Immunological reviews.

[19]  J. Monroe,et al.  B‐cell targeted therapies in human autoimmune diseases: an updated perspective , 2010, Immunological reviews.

[20]  C. Uyttenhove,et al.  B cell depletion reduces the development of atherosclerosis in mice , 2010, The Journal of experimental medicine.

[21]  Ties Boerma,et al.  Global and regional causes of death. , 2009, British medical bulletin.

[22]  T. Kadowaki,et al.  CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity , 2009, Nature Medicine.

[23]  A. Rolink,et al.  Crucial Role for BAFF-BAFF-R Signaling in the Survival and Maintenance of Mature B Cells , 2009, PloS one.

[24]  J. Persson,et al.  Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells , 2008, BMC Immunology.

[25]  F. Lund.  Cytokine-producing B lymphocytes-key regulators of immunity. , 2008, Current opinion in immunology.

[26]  M. Kehry,et al.  B Cell Depletion Inhibits Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice1 , 2008, The Journal of Immunology.

[27]  D. Spandidos,et al.  IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. , 2008, Cardiovascular & hematological agents in medicinal chemistry.

[28]  H. Hase,et al.  TACI attenuates antibody production costimulated by BAFF‐R and CD40 , 2007, European journal of immunology.

[29]  X. Mariette,et al.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production , 2006, Annals of the rheumatic diseases.

[30]  R. Brink.  Regulation of B cell self-tolerance by BAFF. , 2006, Seminars in immunology.

[31]  M. Lopes-Virella,et al.  OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages Published, JLR Papers in Press, June 27, 2006. , 2006, Journal of Lipid Research.

[32]  Martin Bendszus,et al.  Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization , 2006, Stroke.

[33]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[34]  R. Geha,et al.  TACI and BAFF-R mediate isotype switching in B cells , 2005, The Journal of experimental medicine.

[35]  L. Hovgaard,et al.  Inhibition of Tumor Necrosis Factor-&agr; Reduces Atherosclerosis in Apolipoprotein E Knockout Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[36]  J. Kutok,et al.  TNF Family Member B Cell-Activating Factor (BAFF) Receptor-Dependent and -Independent Roles for BAFF in B Cell Physiology1 , 2004, The Journal of Immunology.

[37]  M. Duddy,et al.  Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?1 , 2004, The Journal of Immunology.

[38]  M. Seishima,et al.  Lack of Interleukin-1&bgr; Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[39]  J. Tschopp,et al.  BAFF is a survival and maturation factor for mouse B cells , 2002, European journal of immunology.

[40]  M. Rosenfeld.  Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Xinghua Zhou,et al.  Transfer of CD4+ T Cells Aggravates Atherosclerosis in Immunodeficient Apolipoprotein E Knockout Mice , 2000, Circulation.

[42]  V. Pistoia,et al.  Production of cytokines by human B cells in health and disease. , 1997, Immunology today.

[43]  A. Tall,et al.  IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.